干扰素联合布地奈德治疗呼吸道合胞病毒感染引起的肺内感染临床效果评价研究

Clinical Evaluation of Interferon Combined with Budesonide in the Treatment of Pulmonary Infection Caused by Respiratory Syncytial Virus Infection

目的探究与分析干扰素联合布地奈德治疗呼吸道合胞病毒感染引起的肺内感染临床效果。方法选取2023年1—10月郓城县人民医院收治的80例呼吸道合胞病毒感染引起的肺内感染患儿为研究对象,采取随机数表法分为两组,各40例。对照组采取常规治疗,观察组加用人干扰素a2b注射液联合布地奈德雾化吸入治疗,对比两组临床疗效、主要临床症状改善时间、血清C-反应蛋白(C-reactive protein,CRP)、降钙素原(procalcitonin,PCT)水平,同时对比两组不良反应发生率。结果观察组的临床总有效率为95.00%高于对照组的77.50%,差异有统计学意义(χ^(2)=5.165,P<0.05);观察组咳嗽消失时间、体温恢复正常时间、白细胞计数恢复正常时间以及住院时间均较对照组短,差异有统计学意义(P<0.05);治疗后,观察组PCT以及CRP水平均较对照组低,差异有统计学意义(P<0.05)。两组肝肾功能指标均未观察到明显异常。结论人干扰素a2b注射液联合布地奈德雾化吸入治疗呼吸道合胞病毒感染引起的肺内感染可有效的改善临床症状及体征,缩短主要症状缓解时间,同时可降低炎症反应指标,治疗期间无明显不良反应,安全性较高。

Objective To explore and analyze the clinical effect of interferon combined with budesonide in the treatment of pulmonary infection caused by respiratory syncytial virus infection.Methods A total of 80 children with pulmonary infection caused by respiratory syncytial virus admitted to Yuncheng County People's Hospital from January 2023 to October 2023 were selected as the research objects.According to the random number table method,they were divided into two groups,with 40 cases in each group.The control group was treated with conventional treatment,and the observation group was treated with human interferon a2b injection combined with budesonide aerosol inhalation.The clinical efficacy,improvement time of main clinical symptoms,serum C-reactive protein(CRP)and procalcitonin(PCT)levels were compared between the two groups.The incidence of adverse reactions was compared between the two groups.Results The total effective rate of the observation group was 95.00%,which was higher than 77.50%of the control group,and the difference was statistically significant(χ^(2)=5.165,P<0.05).The cough disappearance time,body temperature recovery time,white blood cell count recovery time and hospitalization time of the observation group were shorter than those of the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of PCT and CRP in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).No obvious abnormalities were observed in liver and kidney function indexes in both groups.Conclusion Human interferon a2b injection combined with budesonide aerosol inhalation in the treatment of pulmonary infection caused by respiratory syncytial virus infection can effectively improve clinical symptoms and signs,shorten the time of relief of main symptoms,and reduce inflammatory response indicators,with no obvious adverse reactions during treatment and high safety.